Crossmark

MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+

Crossref DOI link: https://doi.org/10.1016/j.rppnen.2016.03.009

Published Online: 2025-03-18

Published Print: 2016-09-30

Update policy: https://doi.org/10.1080/tandf_crossmark_01

Authors

Barata, F.

Queiroga, H.

Teixeira, E.

Almodovar, M.T.

Parente, B.

Soares, M.
Funding

Funding for this research was provided by:

Roche Farmacêutica Química, Lda
License Information

Version of Record valid from 2016-09-30
More Information

Peer Review Statement: The publishing and review policy for this title is described in its Aims & Scope.

Aim & Scope: http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=tpul19

Publication History

Published: 2025-03-18

Document is current

Any future updates will be listed below